Table 3.

Outcomes of younger (<60 years) Black and White patients with AML treated on the CALGB/Alliance study protocols

Black patientsWhite patients
Outcomen = 72n = 777Pa
Early death, n (%)7 (10)46 (6)0.20
CR, n (%)51 (71)554 (71)1.00
Relapse rate, n (%)36 (71)328 (59)0.14
DFS0.02
 Median, years0.81.4
 Disease-free at 3 years, % (95% CI)25 (15–38)38 (34–42)
OS0.02
 Median, years1.21.8
 Alive at 3 years, % (95% CI)29 (19–40)42 (38–45)
  • NOTE: The median number of cycles of consolidation chemotherapy was 2 (range, 1–4) for Black patients and 1 (range, 1–4) for White patients (P = 0.09).

  • Abbreviation: CI, confidence interval.

  • aP values for early death, CR, and relapse rate are from Fisher exact test. P values for the time to event variables are from the log-rank test and compare the two groups: Black and White patients with AML.